2. Would this testing and drug therapy be useful for other types of cancer?
It is possible, since KRAS mutations are found in other cancers. This is a focus for medical researchers, but it may be some time before the clinical utility of the testing and therapy in other cancers is determined.
3. Is it necessary to repeat a KRAS mutation test?
This is not usually necessary but might occur if the health practitioner thought that the first sample tested might have been insufficient. In some cases, a health care provider may order a KRAS test that detects a mutation in another part of the DNA chain or another more rare KRAS mutation. Sometimes metastatic tumors may be not be accessible or have limited tissue for testing. In these cases, a sample (if available) from an individual's primary cancer may be obtained for testing. Frequently, if the primary tumor has a KRAS mutation, so will the metastatic tumor.
This article was last reviewed on May 29, 2013. | This article was last modified on December 30, 2013.
The review date indicates when the article was last reviewed from beginning to end to ensure that it reflects the most current science. A review may not require any modifications to the article, so the two dates may not always agree.
The modified date indicates that one or more changes were made to the article. Such changes may or may not result from a full review of the article, so the two dates may not always agree.